Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Frexalimab, Brivekimig, or Rilzabrutinib for primary focal segmental glomerulosclerosis or minimal change disease; the study i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Segmental Glomerulosclerosis
• Minimal Change Disease

Drugs mentioned

• Brivekimig
• Frexalimab (SAR441344)
• Rilzabrutinib (rilzabrutinib)

Snippet

Sponsor: Sanofi | Conditions: Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion | Phase 2 | Status: RECRUITING